Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05299125
Title Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations (AMIGO-1)
Acronym AMIGO-1
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Latin American Cooperative Oncology Group
Indications
Therapies
Age Groups: senior | adult
Covered Countries BRA


No variant requirements are available.